191 related articles for article (PubMed ID: 15564778)
1. Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma.
Matsushita M; Yamamoto T; Nishioka K
Int Arch Allergy Immunol; 2004 Dec; 135(4):348-56. PubMed ID: 15564778
[TBL] [Abstract][Full Text] [Related]
2. Role of monocyte chemoattractant protein-1 and its receptor,CCR-2, in the pathogenesis of bleomycin-induced scleroderma.
Yamamoto T; Nishioka K
J Invest Dermatol; 2003 Sep; 121(3):510-6. PubMed ID: 12925209
[TBL] [Abstract][Full Text] [Related]
3. Animal model of sclerotic skin. V: Increased expression of alpha-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma.
Yamamoto T; Nishioka K
Clin Immunol; 2002 Jan; 102(1):77-83. PubMed ID: 11781070
[TBL] [Abstract][Full Text] [Related]
4. Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice.
Yamamoto T; Takahashi Y; Takagawa S; Katayama I; Nishioka K
J Rheumatol; 1999 Dec; 26(12):2628-34. PubMed ID: 10606374
[TBL] [Abstract][Full Text] [Related]
5. Lung interleukin-4 gene expression in a murine model of bleomycin-induced pulmonary fibrosis.
Gharaee-Kermani M; Nozaki Y; Hatano K; Phan SH
Cytokine; 2001 Aug; 15(3):138-47. PubMed ID: 11554783
[TBL] [Abstract][Full Text] [Related]
6. Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma.
Yamamoto T; Nishioka K
J Invest Dermatol; 2004 Jan; 122(1):44-50. PubMed ID: 14962088
[TBL] [Abstract][Full Text] [Related]
7. Potential roles of interleukin-17A in the development of skin fibrosis in mice.
Okamoto Y; Hasegawa M; Matsushita T; Hamaguchi Y; Huu DL; Iwakura Y; Fujimoto M; Takehara K
Arthritis Rheum; 2012 Nov; 64(11):3726-35. PubMed ID: 22833167
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma.
Matsushita M; Yamamoto T; Nishioka K
Clin Exp Immunol; 2005 Mar; 139(3):429-38. PubMed ID: 15730388
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of TGF-beta1 in the sclerotic skin in bleomycin-'susceptible' mouse strains.
Oi M; Yamamoto T; Nishioka K
J Med Dent Sci; 2004 Mar; 51(1):7-17. PubMed ID: 15137460
[TBL] [Abstract][Full Text] [Related]
10. Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma.
Yamamoto T; Takagawa S; Katayama I; Nishioka K
Clin Immunol; 1999 Jul; 92(1):6-13. PubMed ID: 10413648
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
[TBL] [Abstract][Full Text] [Related]
12. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis.
Distler JH; Jüngel A; Kowal-Bielecka O; Michel BA; Gay RE; Sprott H; Matucci-Cerinic M; Chilla M; Reich K; Kalden JR; Müller-Ladner U; Lorenz HM; Gay S; Distler O
Arthritis Rheum; 2005 Mar; 52(3):856-64. PubMed ID: 15751077
[TBL] [Abstract][Full Text] [Related]
13. IL-13 receptor alpha2 promotes epithelial cell regeneration from radiation-induced small intestinal injury in mice.
Kawashima R; Kawamura YI; Kato R; Mizutani N; Toyama-Sorimachi N; Dohi T
Gastroenterology; 2006 Jul; 131(1):130-41. PubMed ID: 16831597
[TBL] [Abstract][Full Text] [Related]
14. Disruption of tumor necrosis factor receptor p55 impairs collagen turnover in experimentally induced sclerodermic skin fibroblasts.
Murota H; Hamasaki Y; Nakashima T; Yamamoto K; Katayama I; Matsuyama T
Arthritis Rheum; 2003 Apr; 48(4):1117-25. PubMed ID: 12687556
[TBL] [Abstract][Full Text] [Related]
15. A CD40-CD154 interaction in tissue fibrosis.
Kawai M; Masuda A; Kuwana M
Arthritis Rheum; 2008 Nov; 58(11):3562-73. PubMed ID: 18975310
[TBL] [Abstract][Full Text] [Related]
16. Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet.
Lakos G; Melichian D; Wu M; Varga J
Pathobiology; 2006; 73(5):224-37. PubMed ID: 17314493
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells.
Jakubzick C; Choi ES; Joshi BH; Keane MP; Kunkel SL; Puri RK; Hogaboam CM
J Immunol; 2003 Sep; 171(5):2684-93. PubMed ID: 12928422
[TBL] [Abstract][Full Text] [Related]
18. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma.
Wu MH; Yokozeki H; Takagawa S; Yamamoto T; Satoh T; Kaneda Y; Katayama I; Nishioka K
Gene Ther; 2004 Jan; 11(2):170-80. PubMed ID: 14712301
[TBL] [Abstract][Full Text] [Related]
20. Local injection of latency-associated peptide, a linker propeptide specific for active form of transforming growth factor-beta1, inhibits dermal sclerosis in bleomycin-induced murine scleroderma.
Nakamura-Wakatsuki T; Oyama N; Yamamoto T
Exp Dermatol; 2012 Mar; 21(3):189-94. PubMed ID: 22188586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
